In AML, TRIB2 overexpression results in an increase in BCL2 expression and these cells can be target by BCL2 inhibition with venetoclax (ABT-199), a BCL2-domain mimetic [70]. The gene discussed is TRIB2; the disease is acute myeloid leukemia.